U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07443956) titled 'Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis' on Feb. 11.
Brief Summary: This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI >=27.
Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken.
The primary objective will be to assess the changes seen in the joint, fat and skin t...